Kossenas Konstantinos, Georgopoulos Filippos
Surgery, University of Nicosia Medical School, Nicosia, CYP.
Gastroenterology, Al Zahra Hospital Dubai, Dubai, ARE.
Cureus. 2023 Dec 1;15(12):e49780. doi: 10.7759/cureus.49780. eCollection 2023 Dec.
Robotic gastrectomy has been gaining ground in the past 20 years. This study aims to (a) provide an updated and all-encompassing comprehensive review including post-operative outcomes, rate of complications, surgical efficiency and costs, pathology, overall survival, mortality and recurrence, and disease-free survival of robotic versus laparoscopic gastrectomy, (b) report research gaps, and (c) identify ongoing or forthcoming clinical trials that could potentially shed light on underreported findings within the existing literature. Regarding the methodology, PubMed and Google Scholar were searched for randomized controlled trials, systematic reviews, and meta-analyses published between January 2012 and October 2023. ClinicalTrials.gov was searched for related clinical trials currently underway or recruiting. Robotic gastrectomy, when compared to laparoscopic gastrectomy, for the treatment of gastric cancer, performs equally well or shows superiority in terms of the length of hospitalization, overall complications rates, rate of conversion to open surgery, surgical complications, anastomotic leakage, pancreatic complications, blood loss, mortality rates, time to first flatus, time to oral intake, distal and proximal resection margins, recurrence rate, reoperation rates, and overall survival. However, it is associated with higher costs and longer operative time. Parameters such as duodenal stump leakage, anastomosis stenosis, intestinal obstruction, ileus, delayed gastric emptying, wound complications, acute pancreatitis, pancreatic fistula, direct costs, time to initiation of adjuvant chemotherapy, postoperative morbidity, recurrence, and disease-free survival are currently underreported in the literature and necessitate for further research. Lastly, four clinical trials are currently underway or recruiting that could possibly bridge the research gap.
在过去20年里,机器人胃癌切除术逐渐得到广泛应用。本研究旨在:(a)提供一份最新的、全面的综述,涵盖机器人与腹腔镜胃癌切除术的术后结果、并发症发生率、手术效率和成本、病理学、总生存率、死亡率和复发率以及无病生存率;(b)报告研究空白;(c)确定正在进行或即将开展的临床试验,这些试验可能有助于阐明现有文献中未充分报道的发现。关于研究方法,在PubMed和谷歌学术上检索了2012年1月至2023年10月发表的随机对照试验、系统评价和荟萃分析。在ClinicalTrials.gov上检索了目前正在进行或招募患者的相关临床试验。与腹腔镜胃癌切除术相比,机器人胃癌切除术在治疗胃癌时,在住院时间、总体并发症发生率、转为开放手术的比例、手术并发症、吻合口漏、胰腺并发症、失血量、死亡率、首次排气时间、开始经口进食时间、远端和近端切缘、复发率、再次手术率和总生存率等方面表现相当或更具优势。然而,它的成本更高,手术时间更长。十二指肠残端漏、吻合口狭窄、肠梗阻、肠麻痹、胃排空延迟、伤口并发症、急性胰腺炎、胰瘘、直接成本、辅助化疗开始时间、术后发病率、复发率和无病生存率等参数目前在文献中报道不足,需要进一步研究。最后,目前有四项临床试验正在进行或招募患者,这可能有助于填补研究空白。